SEC Form 4 · accession 0000899243-19-000289
Apellis Pharmaceuticals, Inc. · APLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald Chan
Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 3, 2019 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492422
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $13.19 | Jan 1, 2019 | A | 17,580 | A | — | Dec 31, 2028 | Common Stock | 17,580 | 17,580 | D |
Explanation of responses
- F1This option was granted on January 1, 2019 and will vest in four equal quarterly installments on April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020, subject to continued service as a director.